Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DMEPOS fee schedule update implements mandated cuts

This article was originally published in The Gray Sheet

Executive Summary

CMS releases fee schedule Nov. 7 for Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS) implementing mandated fee cuts of 9.5% for 2009 for items included in round 1 of the DMEPOS competitive bidding program, which was delayed until 2010 (1"The Gray Sheet" July 14, 2008, p. 18). Six oxygen-generating portable equipment codes are exempt and will not get a fee cut

You may also be interested in...



Medicare Bill Passed By Congress Delays DMEPOS Bidding Program

An embattled durable medical equipment prosthetics, orthotics and supplies (DMEPOS) competitive bidding program that just got off the ground will likely come to a halt in the coming weeks now that Congress has passed a broad-based Medicare bill

Changes To EU Pharma Reform: More Questions Than Answers?

In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.

Probiotics And Cold Remedies Boost Recordati In 2023

Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT026794

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel